

Patient-Reported Outcomes and Changes in DMARD Therapy Among Psoriatic Arthritis Patients Treated in Routine Clinical Practice



Kyra Mulder, Zhaohui Su, Lauren Stevens, Pam Kumparatana, Stefan Weiss | OM1, Inc, Boston, MA, USA

Background

Patient-reported outcomes (PROs) are used in clinical trials to assess impact of treatment on symptom control and quality of life. Evidence is lacking on impact of PRO monitoring in routine clinical practice.

Methods

The OM1 platform links structured and unstructured data from electronic medical records (EMR) and other sources in a continuous manner. Among 37,301 patients from the OM1 PremiOM-PsA dataset treated by rheumatologists, changes in disease-modifying antirheumatic drug(s) (DMARD) therapy were identified. Baseline RAPID3 scores were compared to RAPID3 scores at 90, 180, and 365 days following DMARD change.

Objective

To examine the role of PROs in routine clinical practice therapy decisions among psoriatic arthritis (PsA) patients.

Results

This analysis included 37,301 patients treated with a DMARD. Overall, 24.7% of patients treated with DMARDs reported at least one RAPID3. In linear mixed models, patients with a DMARD change (n=2,722) had worse RAPID3 scores at baseline than those who did not (4.5 v. 3.8, p<0.0001). RAPID3 scores reported in the 30 days pre-therapy change (mean±SD=4.5±2.1) were worse than scores reported at 90 days (4.2±2.1, p<0.0001), 180 days (4.2±2.2, p<0.0001) and 365 days (4.3±2.2, p<0.0001) post-therapy change.

Main Findings

RAPID3 is a simple mechanism to assess the impact of DMARD therapy on PsA severity. Dermatologists treating PsA should consider incorporating RAPID3 into clinical practice to guide treatment.

Figure 1. Average RAPID3 Among Patients with ≥1 DMARD Switch




Table 1. Patient Demographics (N = 37,301)

Characteristic	N (%)	
Age	Mean (SD)	52.94 (13.4)
	Median (IQR)	54 (44 - 63)
	Min, Max	5, 89
Sex	Female	22,154 (59.4%)
Race	Asian	418 (1.1%)
	Black or African American	796 (2.1%)
	Other	321 (0.9%)
	White	27,644 (74.1%)
	Unknown	8,122 (21.8%)

Conferences Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023. New Orleans, LA, USA

References 1.Coates LC, Tillett W, Shaddick G, Pincus T, Kavanaugh A, Helliwell PS. Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. Arthritis Care Res (Hoboken). 2018 Aug;70(8):1198-1205. doi: 10.1002/acr.23460. Epub 2018 Jun 28. PMID: 29112801.